BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 22091593)

  • 1. Treating multiple sclerosis with natalizumab.
    Iaffaldano P; Lucchese G; Trojano M
    Expert Rev Neurother; 2011 Dec; 11(12):1683-92. PubMed ID: 22091593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE
    Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A; Tintoré M
    Neurologia; 2011; 26(6):357-68. PubMed ID: 21193250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Natalizumab in the treatment of multiple sclerosis].
    Horga A; Horga de la Parte JF
    Rev Neurol; 2007 Sep 1-15; 45(5):293-303. PubMed ID: 17876741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for the selection, treatment, and management of patients utilizing natalizumab therapy for multiple sclerosis.
    Foley J
    Am J Manag Care; 2010 Jun; 16(6 Suppl):S178-83. PubMed ID: 20615054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Natalizumab in multiple sclerosis: unclear patient benefits].
    Schipper JP
    Ned Tijdschr Geneeskd; 2007 Apr; 151(15):852-5. PubMed ID: 17472115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
    Engelhardt B; Kappos L
    Neurodegener Dis; 2008; 5(1):16-22. PubMed ID: 18075270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis.
    Planas R; Jelčić I; Schippling S; Martin R; Sospedra M
    Eur J Immunol; 2012 Mar; 42(3):790-8. PubMed ID: 22144343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of natalizumab in the treatment of multiple sclerosis.
    Coyle PK
    Am J Manag Care; 2010 Jun; 16(6 Suppl):S164-70. PubMed ID: 20615052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab: bench to bedside and beyond.
    Rudick R; Polman C; Clifford D; Miller D; Steinman L
    JAMA Neurol; 2013 Feb; 70(2):172-82. PubMed ID: 23128399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of natalizumab in multiple sclerosis: current perspectives.
    Gandhi S; Jakimovski D; Ahmed R; Hojnacki D; Kolb C; Weinstock-Guttman B; Zivadinov R
    Expert Opin Biol Ther; 2016 Sep; 16(9):1151-62. PubMed ID: 27413840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natalizumab: bound to rebound?
    Schiess N; Calabresi PA
    Neurology; 2009 Feb; 72(5):392-3. PubMed ID: 19188569
    [No Abstract]   [Full Text] [Related]  

  • 14. Natalizumab therapy for multiple sclerosis.
    Derfuss T; Kuhle J; Lindberg R; Kappos L
    Semin Neurol; 2013 Feb; 33(1):26-36. PubMed ID: 23709210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons for clinical trials from natalizumab in multiple sclerosis.
    Chaudhuri A
    BMJ; 2006 Feb; 332(7538):416-9. PubMed ID: 16484271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango.
    Gupta S; Weinstock-Guttman B
    Expert Opin Biol Ther; 2014 Jan; 14(1):115-26. PubMed ID: 24289270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple sclerosis, natalizumab, and PML: helping patients decide.
    Rudick RA
    Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S18-23. PubMed ID: 22123928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The return of natalizumab: weighing benefit against risk.
    Goodin D
    Lancet Neurol; 2006 May; 5(5):375-7. PubMed ID: 16632301
    [No Abstract]   [Full Text] [Related]  

  • 19. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M; Päivärinta M; Sonninen P; Parkkola R; Vuorinen T; Erälinna JP
    Duodecim; 2013; 129(7):765-70. PubMed ID: 23720945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PML risk and natalizumab: more questions than answers.
    Ransohoff RM
    Lancet Neurol; 2010 Mar; 9(3):231-3. PubMed ID: 20117056
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.